What is Epothilone A, and how is it used in research?

Epothilone A is a natural product that stabilizes microtubules, similar to paclitaxel. It is commonly used in cancer research to study cell division and apoptosis, making it a potential payload in ADCs.

What advantages does Epothilone A offer over other microtubule stabilizers in ADCs?

Epothilone A shows activity against tumors that are resistant to other microtubule-stabilizing agents like paclitaxel, making it a valuable alternative in ADC payload design.

What are the primary side effects of using Epothilone A in preclinical studies?

Common side effects in preclinical models include neuropathy and cytotoxicity in non-target tissues. However, these effects can be mitigated in ADCs through targeted delivery to tumor cells.

Can Epothilone A be used in drug-resistant cancer models?

Yes, Epothilone A has shown efficacy in models of drug-resistant cancers, including those resistant to paclitaxel, due to its ability to bind distinct sites on tubulin.

Is Epothilone A suitable for use in immuno-oncology research?

While primarily a cytotoxic agent, Epothilone A can be integrated into immuno-oncology strategies, particularly in ADCs targeting tumor-associated antigens for enhanced cancer cell elimination.

Epothilone A (CAT#: ADC-P-048)

ADCs Toxins, Epothilone A exhibits kinetics similar to paclitaxel by inducing tubulin polymerization in vitro and producing enhanced microtubule stability and bundling in cultured cells. In contrast to paclitaxel, Epothilone A exhibits a greater cytotoxicity against P-glycoprotein-expressing multidrug resistant cells (IC50= 20 nM for MDR CCRF-CEM/VBL100 cells).Epo A is cytotoxic to human T-24 bladder carcinoma cells (IC50 = 0.05 µM in vitro) but has poor pharmacological properties and is 2-fold less potent in stabilizing microtubules compared to epothilone B.

Product Information

Description
ADCs Toxins, Epothilone A exhibits kinetics similar to paclitaxel by inducing tubulin polymerization in vitro and producing enhanced microtubule stability and bundling in cultured cells. In contrast to paclitaxel, Epothilone A exhibits a greater cytotoxicity against P-glycoprotein-expressing multidrug resistant cells (IC50= 20 nM for MDR CCRF-CEM/VBL100 cells).Epo A is cytotoxic to human T-24 bladder carcinoma cells (IC50 = 0.05 µM in vitro) but has poor pharmacological properties and is 2-fold less potent in stabilizing microtubules compared to epothilone B.

Classification
Microtubule Inhibitors

Molecular Weight
493.7

Purity
95%

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-P-048. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

Epothilone A proved to be an effective compound in our cancer cell assays, particularly showing significant cytotoxicity against T-24 bladder carcinoma cells. Its tubulin polymerization ability was impressive in stabilizing microtubules.

Excellent

In our ADC research, Epothilone A was an exceptional cytotoxic agent. Its ability to target multidrug-resistant cells made it invaluable in enhancing the efficacy of antibody-drug conjugates.

Excellent

When using Epothilone A in ADC development, its cytotoxic effects were apparent, especially against multidrug-resistant cells. The compound showed promise in enhancing drug delivery systems for targeted therapies.

Excellent

I tested Epothilone A in multidrug-resistant cell lines and observed superior cytotoxic effects compared to paclitaxel. This compound is especially potent against cells expressing P-glycoprotein.

Excellent

Our lab employed Epothilone A in ADC experiments, and its efficacy against MDR cells was impressive. Its microtubule-stabilizing properties made it an ideal choice for our conjugate development.

Q: 1: What is Epothilone A, and how is it used in research?
A: Epothilone A is a natural product that stabilizes microtubules, similar to paclitaxel. It is commonly used in cancer research to study cell division and apoptosis, making it a potential payload in ADCs.
Q: 2: What advantages does Epothilone A offer over other microtubule stabilizers in ADCs?
A: Epothilone A shows activity against tumors that are resistant to other microtubule-stabilizing agents like paclitaxel, making it a valuable alternative in ADC payload design.
Q: 3: What are the primary side effects of using Epothilone A in preclinical studies?
A: Common side effects in preclinical models include neuropathy and cytotoxicity in non-target tissues. However, these effects can be mitigated in ADCs through targeted delivery to tumor cells.
Q: 4: Can Epothilone A be used in drug-resistant cancer models?
A: Yes, Epothilone A has shown efficacy in models of drug-resistant cancers, including those resistant to paclitaxel, due to its ability to bind distinct sites on tubulin.
Q: 5: Is Epothilone A suitable for use in immuno-oncology research?
A: While primarily a cytotoxic agent, Epothilone A can be integrated into immuno-oncology strategies, particularly in ADCs targeting tumor-associated antigens for enhanced cancer cell elimination.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

For Research Use Only. NOT FOR CLINICAL USE.

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.